Market Place
Sourcing Support
AstraZeneca asthma drug more effective during attack than steroids
30 Nov 2024 //
REUTERS
Fasenra approved in the EU for eosinophilic granulomatosis (EGPA)
29 Oct 2024 //
PRESS RELEASE
AstraZeneca`s Fasenra Approved in the US for Rare Blood Vessel Disease
19 Sep 2024 //
CONTRACTPHARMA
AstraZeneca`s Biologic Fasenra (Benralizumab) Receives Approvals In U.S
17 Sep 2024 //
FDA
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
12 Apr 2024 //
PRESS RELEASE
AstraZeneca steps up to show Fasenra helping patients step out
25 Mar 2024 //
FIERCE PHARMA
Phase III data published show remission is an achievable goal in EGPA
23 Feb 2024 //
BUSINESSWIRE
FASENRA met the primary endpoint in the MANDARA Phase III trial in EGPA
11 Sep 2023 //
BUSINESSWIRE
AstraZeneca unifies patient-doc messaging for asthma blockbuster
17 May 2023 //
FIERCE PHARMA
AstraZeneca`s Fasenra produces mixed results in eosinophilic oesophagitis study
25 Oct 2022 //
PRESS RELEASE
FDA declines to approve AstraZeneca treatment for chronic nasal condition
15 Mar 2022 //
REUTERS
GSK looks to stand out in the severe asthma space for kids 6 to 11 years old
25 Jan 2022 //
ENDPTS
AZ announces US fast track designation for IL-5 inhibitor Fasenra
08 Nov 2021 //
PHARMATIMES
AstraZeneca drug evaluated in nine eosinophilic diseases
22 Apr 2021 //
PHARMAFILE
Astrazeneca launches Benralizumab for asthma patients; Stock skyrockets 11%
22 Apr 2021 //
INDIAINFOLINE
Fasenra eliminated oral corticosteroid use in a majority of OCS-dependent
30 Oct 2020 //
PRESS RELEASE
FASENRA® eliminated oral corticosteroid use in a majority of OCS
30 Oct 2020 //
BUSINESSWIRE
Fasenra shows PhIII topline data for nasal polyps, tight race with GSK`s Nucala
11 Sep 2020 //
ENDPTS
New analyses from Breztri Aerosphere Phase III ETHOS trial to be presented
07 Sep 2020 //
PRESS RELEASE
AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma
05 Aug 2020 //
PHARMATIMES
Determination of Regulatory Review Period for Purposes of Patent ; FASENRA
04 Mar 2020 //
FEDERALREGISTER
AstraZeneca`s Fasenra Approved for Asthma Using an Auto-Inject Pen
05 Oct 2019 //
BIOSPACE
AstraZeneca AB`s Fasenra (Benralizumab) Receives Supplemental Approval in US
04 Oct 2019 //
FDA
AstraZeneca respiratory business gets boost from 3-drug inhaler results
29 Aug 2019 //
REUTERS
USFDA grants orphan drug status to Fasenra eosinophilic oesophagitis treatment
28 Aug 2019 //
PHARMABIZ
AZ bags two extensions in latest CHMP decisions
01 Jul 2019 //
PHARMATIMES
AstraZeneca’s COPD triplet Breztri nabs first nod from Japan
20 Jun 2019 //
FIERCE PHARMA
GlaxoSmithKline`s Nucala scores convenience boost with at-home dosing options
08 Jun 2019 //
FIERCE PHARMA
As rivals crowd in, Can Novartis` Xolair remain a blockbuster?
04 Jun 2019 //
FIERCE PHARMA
Sanofi, Regeneron dive deep on asthma in debut digital awareness campaign
04 Jun 2019 //
FIERCE PHARMA
AZ`s Fasenra benefits hold up for 2 years: analysis
20 May 2019 //
FIERCE PHARMA
AstraZeneca`s Fasenra keeps the heat on GSK`s Nucala with new phase 2 data
05 Apr 2019 //
FIERCE PHARMA
Fasenra granted Orphan Drug Designation by FDA
07 Feb 2019 //
PHARMA TIMES
GSK looks to oncology for growth as Advair generic hits
06 Feb 2019 //
FIERCE PHARMA
AstraZeneca Departures Continue as Medical Chief Bohen Exits
14 Jan 2019 //
BLOOMBERG
NICE recommends Fasenra injection as asthma alternative
05 Jan 2019 //
PHARMA TIMES
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease
28 Nov 2018 //
PHARMA TIMES
ICER On Asthma Biologics: 50%-79% Price Discounts Needed
15 Nov 2018 //
PHARMA INTEL
GSK execs change their tune as AZ, Sanofi heap pressure on Nucala
08 Nov 2018 //
FIERCE PHARMA
Roche, Novartis grab FDA OK for new version of aging blockbuster Xolair
04 Oct 2018 //
FIERCE PHARMA
ICER finds top asthma biologics overpriced
26 Sep 2018 //
BIOPHARMA DIVE
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma
17 Sep 2018 //
PHARMA TIMES
AZ teams with Geisinger on EHR apps to connect doctors and patients
30 Jul 2018 //
FIERCE PHARMA
NICE says yes to AZ’s Fasenra, but only when its GSK rival can’t be used
20 Jul 2018 //
FIERCE PHARMA
NICE backs AZ’ asthma biologic Fasenra
16 Jul 2018 //
PHARMA TIMES
